HUMA Humacyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HUMA

Price (delayed)

$1.49

Market cap

$330.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$347.96M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3
Highlights
HUMA's debt is down by 20% year-on-year
HUMA's EPS has dropped by 127% since the previous quarter but it is up by 14% year-on-year
The quick ratio is down by 46% YoY but it is up by 9% QoQ
HUMA's net income has dropped by 139% since the previous quarter and by 26% year-on-year
The company's equity has shrunk by 68% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of HUMA

HUMA stock price

How has the Humacyte stock price performed over time
Intraday
6.43%
1 week
16.41%
1 month
61.12%
1 year
-43.35%
YTD
55.13%
QTD
145.59%

Financial performance

How have Humacyte's revenue and profit performed over time
Revenue
$2.02M
Gross profit
-$9.58M
Operating income
-$113.89M
Net income
-$97.59M
Gross margin
-475%
Net margin
-4,840.8%
HUMA's net margin has dropped by 142% since the previous quarter but it has surged by 68% year-on-year
HUMA's net income has dropped by 139% since the previous quarter and by 26% year-on-year
Humacyte's operating margin has surged by 74% YoY but it has decreased by 6% QoQ
The gross margin is down by 26% QoQ

Price vs fundamentals

How does HUMA's price correlate with its fundamentals

Growth

What is Humacyte's growth rate over time

Valuation

What is Humacyte stock price valuation
P/E
N/A
P/B
28.46
P/S
146.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
172.6
HUMA's EPS has dropped by 127% since the previous quarter but it is up by 14% year-on-year
The company's equity has shrunk by 68% YoY
The stock's price to sales (P/S) is 22% less than its last 4 quarters average of 176.7

Efficiency

How efficient is Humacyte business performance
HUMA's return on sales has dropped by 198% since the previous quarter but it has surged by 67% year-on-year
HUMA's return on invested capital has dropped by 194% since the previous quarter and by 26% year-on-year
Humacyte's return on assets has shrunk by 166% QoQ and by 52% YoY

Dividends

What is HUMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HUMA.

Financial health

How did Humacyte financials performed over time
HUMA's total assets is 12% higher than its total liabilities
The quick ratio is down by 46% YoY but it is up by 9% QoQ
HUMA's total assets is down by 32% YoY and by 5% QoQ
The debt to equity has soared by 149% year-on-year but it has dropped by 73% since the previous quarter
The company's equity has shrunk by 68% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.